Can I read Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis on EtoBox?

Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis by Jianyang Liu; Helena Idborg; Marina Korotkova; Kristina Lend; Ronald van Vollenhoven; Jon Lampa; Anna Rudin; Dan Nordström; Bjorn Gudbjornsson; Gerdur Gröndal; Till Uhlig; Kim Hørslev-Petersen; Merete Lund Hetland; Mikkel Østergaard; Michael Nurmohamed; Per-Johan Jakobsson is a Medicine article available to read on EtoBox.

What is Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis about?

## Background Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient’s response to these therapies. Prostanoids, encompassing prostaglandins, prostacyclins, and thromboxanes, are potent lipid mediators implicated in RA progression. Nevertheless, the influence of DMARDs on prostanoid biosynthesis in RA patients remains poorly understood. This study aims to assess the impact of various DMARDs on urinary prostanoids levels and to explore whether urinary prostanoid profiles correlate with disease activity or response to therapy. ## Methods This study included 152 Swedish female patients with early RA, all rheumatoid factor (RF) positive, enrolled in the NORD-STAR trial (registration number: NCT01491815). Participants were randomized into four therapeutic regimes: methotrexate (MTX) combined with (i) prednisolone (arm ACT), (ii) TNF-α blocker certolizumab pegol (arm CZP), (iii) CTLA-4Ig abatacept (arm ABA), or (iv) IL-6R blocker tocilizumab (arm TCZ). Urine samples, collected before start of treatment and at 24 weeks post-treatment, were analyzed for tetranor-prostaglandin E

Who reads Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis?

Author

Jianyang Liu; Helena Idborg; Marina Korotkova; Kristina Lend; Ronald van Vollenhoven; Jon Lampa; Anna Rudin; Dan Nordström; Bjorn Gudbjornsson; Gerdur Gröndal; Till Uhlig; Kim Hørslev-Petersen; Merete Lund Hetland; Mikkel Østergaard; Michael Nurmohamed; Per-Johan Jakobsson

Publisher

Springer Science and Business Media LLC

Published

2024

Language

EN

Field

Medicine (Health Sciences)